Genprex Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.52
- Today's High:
- $0.5499
- Open Price:
- $0.52
- 52W Low:
- $0.425
- 52W High:
- $1.94
- Prev. Close:
- $0.515
- Volume:
- 93162
Company Statistics
- Market Cap.:
- $31.25 million
- Book Value:
- 0.232
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -74.43%
- Return on Equity TTM:
- -134.27%
Company Profile
Genprex Inc had its IPO on 2018-03-29 under the ticker symbol GNPX.
The company operates in the Healthcare sector and Biotechnology industry. Genprex Inc has a staff strength of 30 employees.
Stock update
Shares of Genprex Inc opened at $0.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.52 - $0.55, and closed at $0.55.
This is a +6.78% increase from the previous day's closing price.
A total volume of 93,162 shares were traded at the close of the day’s session.
In the last one week, shares of Genprex Inc have increased by +4.54%.
Genprex Inc's Key Ratios
Genprex Inc has a market cap of $31.25 million, indicating a price to book ratio of 2.0266 and a price to sales ratio of 0.
In the last 12-months Genprex Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-30036470. The EBITDA ratio measures Genprex Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Genprex Inc’s operating margin was 0% while its return on assets stood at -74.43% with a return of equity of -134.27%.
In Q2, Genprex Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Genprex Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Genprex Inc’s profitability.
Genprex Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3321. Its price to sales ratio in the trailing 12-months stood at 0.
Genprex Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.91 million
- Total Liabilities
- $3.86 million
- Operating Cash Flow
- $-20000.00
- Capital Expenditure
- $20000
- Dividend Payout Ratio
- 0%
Genprex Inc ended 2024 with $15.91 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.91 million while shareholder equity stood at $12.05 million.
Genprex Inc ended 2024 with $0 in deferred long-term liabilities, $3.86 million in other current liabilities, 51979.00 in common stock, $-120010786.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.96 million and cash and short-term investments were $9.96 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Genprex Inc’s total current assets stands at $12.37 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $1.50 million and inventory worth $0.
In 2024, Genprex Inc's operating cash flow was $-20000.00 while its capital expenditure stood at $20000.
Comparatively, Genprex Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.55
- 52-Week High
- $1.94
- 52-Week Low
- $0.425
- Analyst Target Price
- $5.5
Genprex Inc stock is currently trading at $0.55 per share. It touched a 52-week high of $1.94 and a 52-week low of $1.94. Analysts tracking the stock have a 12-month average target price of $5.5.
Its 50-day moving average was $0.68 and 200-day moving average was $0.99 The short ratio stood at 2.05 indicating a short percent outstanding of 0%.
Around 230.6% of the company’s stock are held by insiders while 1588% are held by institutions.
Frequently Asked Questions About Genprex Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.